Loading...
Identifying which individuals with mild cognitive impairment (MCI) will progress to Alzheimer disease has great practical application and should grow in importance as new medications and vaccination strategies are discovered. Laboratory predictive tests would need to enable clinicians to identify vulnerable individuals before the disease is clinically apparent. In a multisite study, researchers developed testing cutoffs for cerebrospinal fluid protein markers amyloid β42 (Aβ42), total tau (T-tau), and phosphorylated tau (P-tau) in 529 AD patients and 304 controls. The researchers then tested the biomarkers' utility for predicting progression to AD by following 729 individuals with MCI for 2 to 11 years (median, 3 years).
Although the biomark…